DexCom, Inc. (DXCM)

US — Healthcare Sector
Peers: PODD  TNDM  ABT  ALGN  SYK  IDXX  VEEV  NOW 

Automate Your Wheel Strategy on DXCM

With Tiblio's Option Bot, you can configure your own wheel strategy including DXCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DXCM
  • Rev/Share 10.606
  • Book/Share 5.7954
  • PB 14.6442
  • Debt/Equity 1.1397
  • CurrentRatio 1.4994
  • ROIC 0.0942

 

  • MktCap 33278121090.0
  • FreeCF/Share 1.4707
  • PFCF 57.8549
  • PE 62.0192
  • Debt/Assets 0.3826
  • DivYield 0
  • ROE 0.2438

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation DXCM Truist -- Buy -- $102 June 16, 2025
Initiation DXCM Goldman -- Buy -- $104 May 30, 2025
Initiation DXCM Mizuho -- Outperform -- $85 April 10, 2025
Upgrade DXCM Redburn Atlantic Neutral Buy $85 $115 Feb. 3, 2025
Upgrade DXCM Robert W. Baird Neutral Outperform $86 $104 Jan. 16, 2025

News

DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
DXCM
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral

DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairman, President and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Jake Leach - Chief Operating Officer Conference Call Participants Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Robbie Marcus - J.P. Morgan Danielle Antalffy - UBS Travis Steed - Bank of America Joanne Wuensch - Citibank Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Capital Markets Chris …

Read More
image for news DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
Here's What Key Metrics Tell Us About DexCom (DXCM) Q4 Earnings
DXCM
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive

The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More
image for news Here's What Key Metrics Tell Us About DexCom (DXCM) Q4 Earnings
Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast
DXCM
Published: February 13, 2025 by: Reuters
Sentiment: Positive

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

Read More
image for news Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast

About DexCom, Inc. (DXCM)

  • IPO Date 2005-04-14
  • Website https://www.dexcom.com
  • Industry Medical - Devices
  • CEO Kevin Ronald Sayer
  • Employees 10200

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.